Buchholz, Mirko; Heiser, Ulrich; Schilling, Stephan; Niestroj, Andre J.; Zunkel, Katrin; Demuth, Hans-Ulrich published the artcile< The first potent inhibitors for human glutaminyl cyclase: synthesis and structure-activity relationship>, SDS of cas: 45434-02-4, the main research area is thiourea imidazolylpropyl human glutaminyl cyclase inhibitor; Alzheimer disease treatment imidazolylpropylthiourea preparation; human glutaminyl cyclase inhibitor imidazolylpropylthiourea library preparation.
The first effective inhibitors for human glutaminyl cyclase (QC) are described. The structures are developed by applying a ligand-based optimization approach starting from imidazole. Screening of derivatives of that heterocycle led to compounds of the imidazol-1-yl-alkyl thiourea type as a lead scaffold. A library of thiourea derivatives was synthesized, resulting in an inhibitory improvement by 2 orders of magnitude, leading to 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea as a potent inhibitor. Systematic exploitation of the scaffold revealed a strong impact on the inhibitory efficacy and resulted in the development of imidazole-propyl-thioamides as another new class of potent inhibitors. A flexible alignment of the most potent compounds of the thioamide and thiourea class and a QC substrate revealed a good match of characteristic features of the mols., which suggests a similar binding mode of both inhibitors and the substrate to the active site of QC.
Journal of Medicinal Chemistry published new progress about Alzheimer disease. 45434-02-4 belongs to class alcohols-buliding-blocks, and the molecular formula is C5H11NO, SDS of cas: 45434-02-4.
Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts